In opposition to the first phase, in the second phase, lung-attached ACE2 expression may be positively correlated with better clinical outcomes, since ACE2 may limit the cytokine storm that underlies the Acute Respiratory Distress Syndrome (ARDS) in COVID-19, while the balance between proinflammatory angiotensin II–angiotensin receptor type 1 (AT1) axis, and the anti-inflammatory angiotensin 1–7—G-coupled Mas receptor (angiotensin 1–7 receptor) axis may also be crucial for level of severity of the second phase (13, 15–19). This evidence concerns the gene AGT and acute respiratory distress syndrome.